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ABSTRACT (119 words) 22 
 23 
 Since 2003, dozens of giant viruses that infect amoebas (GVA), including mimiviruses 24 
and marseilleviruses, have been discovered. These giants appear to be common in our 25 
biosphere. From the onset, their presence and possible pathogenic role in humans have been 26 
serendipitously observed or investigated using a broad range of technological approaches, 27 
including culture, electron microscopy, serology and various techniques based on molecular 28 
biology. The link between amoebal mimiviruses and pneumonia has been the most 29 
documented, with findings that fulfill several of the criteria considered as proof of viral 30 
disease causation. Regarding marseilleviruses, they have been mostly described in 31 
asymptomatic persons, and in a lymph node adenitis. The presence and impact of GVA in 32 
humans undoubtedly deserve further investigation in medicine.  33 
 34 
  35 
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TEXT (2,625 words) 36 
 37 
The emergence of giant viruses of amoebas 38 
The story of giant viruses that infect amoebas (GVA) began with the isolation of the 39 
Mimivirus in 1992 [1;2]. This was made possible by using a strategy that consisted of 40 
inoculating samples on an axenic culture of Acanthamoeba spp. and was implemented to 41 
isolate amoeba-resisting microorganisms such as Legionella spp. [2]. The first mimivirus 42 
isolate was obtained from cooling tower water while investigating a pneumonia outbreak in 43 
England. It took a decade to identify that one of the amoeba-resistant microbes was a giant 44 
virus, which was visible on light microscopy and looked like a Gram-positive coccus. This 45 
was eventually revealed in 2003 in Marseille by using electron microscopy [1;2]. Thus, the 46 
investigation triggered in 1992 by pneumonia cases serendipitously led to discovery of the 47 
largest viruses known so far, which strongly challenge the concept and definition of viruses 48 
[1;3;4]. Moreover, it suggested the link between these GVA and humans and their possible 49 
pathogenicity. 50 
 Dozens of additional mimiviruses, which were classified in the family Mimiviridae, 51 
were isolated in amoebas from environmental water samples collected in various geographical 52 
areas worldwide [5;6]. In addition, these studies led to the discovery of the first viruses of 53 
viruses, named ‘virophages’, which replicate in the viral factories of mimiviral hosts and can 54 
impair their replicative cycle and morphogenesis [7;8]. Moreover, other GVA have been 55 
discovered since 2008 [4;9]. Some were classified in the family Marseilleviridae and others 56 
include pandoraviruses [10;11], Pithovirus sibericum [12], faustoviruses [13] and Mollivirus 57 
sibericum [14], which represent new putative virus families [9]. All these GVA cultured in 58 
amoebas display many unique characteristics that put them on the edge of the virus definition, 59 
and warrant proposing their reclassification as representatives of a fourth ‘TRUC’ (an 60 
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acronym for Things Resisting Uncompleted Classifications) of microbes [15] (reviewed by V. 61 
Sharma et al. [4]). They have been proposed for classification in a new viral order, 62 
Megavirales, alongside other double-stranded DNA viruses [16].  63 
GVA appear to be common in our biosphere; they have been isolated from marine 64 
water, freshwater and soil samples collected in several countries worldwide 65 
(https://www.google.com/maps/d/edit?mid=zA3X4ljlz-uM.kFSrbnCtoBLc) [5;17;18]. This 66 
has been corroborated by metagenomic studies that detected sequences matching these viruses 67 
in similar environmental samples collected in highly diverse geographical areas [19;20] 68 
(reviewed by S. Halary et al. [21]). In addition, their hosts, Acanthamoeba spp. (for most of 69 
these viruses) or Vermamoeba vermiformis (for faustoviruses) are ubiquitous organisms that 70 
are common in human environments, very resistant and described as ‘Trojan horses’ for their 71 
parasitic pathogens [22;23]. Moreover, GVA prevalence was probably underestimated 72 
because 'viral' fractions analyzed were most often obtained by filtration through a 0.2 µm-73 
large pore size, which neglects gigantic virions [20]. Taken together, these findings strongly 74 
suggest that humans are exposed to GVA. Noteworthy, 12% of 242 samples collected from 75 
inanimate surfaces in a Brazilian hospital were positive for Mimivirus DNA by PCR, the 76 
incidence being significantly greater in respiratory isolation facilities, and amoebal lysis was 77 
obtained from 83% of these samples [24].  78 
Other studies have reported the isolation of mimiviruses from oysters [25] and a leech 79 
[26], and their detection by PCR in monkeys and cattle [27]. In addition, a Marseillevirus was 80 
isolated from a diptera [26] and a faustovirus was cultured from culicoides [28]. Moreover, 81 
mimivirus-like sequences were identified in metagenomes generated from bats, rodents, 82 
dromedaries and culicoides, and faustovirus- and pandoravirus-like sequences were detected 83 
in metagenomes generated from culicoides [20;21;28] (reviewed S. Halary et al. [21]). 84 
 85 
 5 
 
Evidence for a causative role of giant viruses of amoebas in pathogenicity 86 
 Causality criteria 87 
 An increasing body of data supports the presence of GVA in humans, and in addition, 88 
the question of the putative pathogenic role of these viruses has been addressed and 89 
documented, mainly for mimiviruses, and more recently for marseilleviruses. Establishing a 90 
causative role of viruses in diseases has been a long journey. Criteria developed since 1840 by 91 
Henle, Loeffler and Koch to prove the etiologic association between an infectious agent and a 92 
specific disease have been deemed less and less appropriate over time [29]. Other criteria for 93 
causative relations were proposed [30], including some specifically applied to viruses in 1937, 94 
1957 and 1976 (Box 1) [31-33]. However, newly discovered viruses challenge existing 95 
postulates, as, for instance, with viruses determining chronic or latent infections. Thus, with 96 
the advent of new technologies and improved knowledge in microbiology and virology, 97 
criteria considered for suspecting or establishing a causality link have drifted considerably. 98 
Notably, sequence-based criteria were introduced in 1996, and metagenomic Koch’s 99 
postulates were finally proposed in 2012 [34;35]. Since 2003, the presence and possible 100 
pathogenic role of GVA has been serendipitously observed or investigated using a broad 101 
range of technological approaches including culture, electron microscopy, serology and 102 
various techniques based on molecular biology, including metagenomics (Table 1). The 103 
findings fulfill several of the criteria considered as proofs of viral disease causation. 104 
 Host cells other than phagocytic amoebas for giant viruses of amoebas 105 
 All GVA have been isolated on cultures of A. castellani, A. polyphaga, or V. 106 
vermiformis [13;36]. Numerous cell lines have been tested for their permissivity to 107 
mimiviruses or marseilleviruses. In experimental inoculation tests, Mimivirus was capable of 108 
entering professional phagocytes, among which various human myeloid cells including 109 
circulating monocytes, monocyte-derived macrophages and myelomonocytic cells, and also 110 
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mouse myeloid cells [37]. Further experiments conducted with mouse macrophages showed a 111 
significant increase in Mimiviral DNA load during a 30-hour period of incubation; in 112 
addition, only approximately one quarter of the macrophages were viable after 30 hours, and 113 
macrophage extracts led to Mimivirus replication within amoebae and to amoebal lysis. These 114 
findings indicated productive infection of macrophage by Mimivirus post-internalization. In 115 
addition, Mimivirus was demonstrated to replicate in total human peripheral blood 116 
mononuclear cells (PBMC), as measured by the tissue culture infective dose method [38]. 117 
Furthermore, Mimivirus was revealed to induce type I IFN production in infected human 118 
PBMC and to inhibit interferon stimulated genes expression in these cells. These findings 119 
question if amoebae are the exclusive hosts for the giant Mimivirus. Moreover, inoculation of 120 
Jurkat cells, which are immortalized human T lymphocyte cells, with a serum sample positive 121 
for Giant blood Marseillevirus (GBM) DNA led to detection of this virus by PCR in the 122 
culture supernatant, and viral DNA and virions were detected within Jurkat cells 21 days post-123 
infection by PCR, fluorescence in situ hybridization, or transmission electron microcopy [39]. 124 
Although GBM was not propagated, these results indicated productive infection of these cells. 125 
It should be considered that the host barrier may be far more limited for GVA than for other 126 
viruses, because GVA infect their hosts by phagocytosis [37]. This was exemplified by the 127 
capability of Mimivirus to enter human macrophages through phagocytosis, and this closely 128 
resembled Mimivirus entry in amoebas [37]. In addition, mimiviruses, marseilleviruses or 129 
faustoviruses have been isolated from different phagocytic protists, including amoebozoa and 130 
chromalveolata, and also mammals, including humans, and also insects [26;48;49].  131 
 Mimivirus 132 
 Serological-only evidence 133 
 Concomitantly with the initial attempts to identify the giant Mimivirus, serological 134 
testing of sera from patients with unexplained pneumonia showed that the strongest 135 
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reactivities were against this amoeba-resisting microbe [40]. Subsequently, the prevalence of 136 
antibodies to Mimivirus was assessed using microimmunofluorescence in several studies, in 137 
most cases in pneumonia patients hospitalized in intensive care units (ICU) (Table 1). IgG 138 
prevalence was most often »10-20% in pneumonia patients, ranging from 0% to 25% [41-44]. 139 
In contrast, it was 0% and 2.3% in intubated control patients without pneumonia and healthy 140 
controls, respectively [41]. Moreover, IgG and IgM elevations or seroconversions were 141 
observed in patients with hospital-acquired pneumonia [44]. The first strong evidence of 142 
infection with a GVA was in a laboratory technician who handled large amounts of Mimivirus 143 
and developed unexplained pneumonia [45]. He exhibited seroconversion to 23 Mimivirus 144 
proteins, as assessed by 2-dimensional gel electrophoresis (2DGE) and Western blotting, 145 
among which 4 proteins were unique to this virus. Interestingly, this story is very similar to 146 
the one that linked Epstein-Barr virus (EBV) to infectious mononucleosis. In 1968, a 147 
laboratory technician who worked with EBV developed infectious mononucleosis and 148 
concurrently exhibited seroconversion to this virus [46]. Positive serology to the Sputnik 149 
virophage was also observed in two patients of Laotian origin who exhibited fever while 150 
returning from Laos [47]. Serological reactivities were obtained by Western blot, 2DGE and 151 
mass spectrometry and targeted two virophage proteins. In addition, one seroconversion could 152 
be shown. The serological detection of Sputnik in humans suggests the exposure of humans to 153 
this virophage, and the concurrent exposure to mimiviruses, which are the Sputnik hosts [7;8]. 154 
Thus, in this study, serological reactivities were also observed to Mamavirus and 155 
Acanthamoeba. No virus was isolated. In addition, a significant association was reported 156 
between antibodies to Mimivirus L71 protein, which harbors collagen-like motifs, and 157 
rheumatoid arthritis in patients [48]. 158 
 PCR 159 
Detection by PCR of GVA in humans has only been conducted to date in clinical 160 
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specimens evaluated for mimiviruses and marseilleviruses [49]. Mimivirus DNA was 161 
screened for in respiratory samples and was first found in 1 of 32 patients with ICU-acquired 162 
pneumonia (Table 1) [41]. Then, mimiviruses were detected by conventional PCR in a 163 
Tunisian patient presenting unexplained pneumonia, concurrently with mimivirus isolation 164 
[50]. Other studies have reported negative PCR testing in human respiratory samples [43;51], 165 
which may mean that mimiviruses are uncommon in this setting, or present at a low titer, but 166 
the main reason may be the substantial genetic diversity within the family Mimiviridae, which 167 
prevents implementation of universal PCR assays [49].  168 
Culture isolation 169 
Two mimiviruses have been isolated to date from clinical samples, in Tunisian 170 
patients with unexplained pneumonia (Table 1). In the first case, LBA111 virus was cultured 171 
from the bronchoalveolar fluid of a 72-year-old woman [50]. The patient was admitted to the 172 
hospital for a 3-day fever with cough, dyspnea and hemoptysis; chest X-ray revealed right 173 
lower lobe consolidation and the white blood cell count was elevated. Concurrently, 174 
antibodies to 9 LBA111 virus proteins were detected by 2D Western blotting. The second 175 
case was a 17-year-old girl admitted for fever (40°C) and cough for 15 days, with lower left 176 
lung opacity, diarrhea, and leukocytosis [52]. In this case, Shan virus was isolated from the 177 
stool; no respiratory sample was available. In addition, another mimivirus, named 178 
Lentillevirus, was isolated from the contact lens storage liquid of a keratitis patient [53]. 179 
Interestingly, its Acanthamoeba host was isolated and revealed to be infected with two 180 
amoeba-resisting bacteria and a virophage, Sputnik2.  181 
 Experimental evidence 182 
Histopathological features of pneumonia, including thickened alveolar walls, 183 
inflammatory infiltrates and diffuse alveolar damage were observed in an experimental mouse 184 
model following intracardiac Mimivirus inoculation (Table 1) [54]. No other experiment 185 
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model of inoculation to animal has been conducted to date for another GVA. Such approach is 186 
of strong interest but questions on the most appropriate inoculum and inoculation route. 187 
 Marseilleviruses 188 
 The first hint of the presence of a marseillevirus in humans was serendipitously 189 
obtained during a metagenomic study that targeted bacterial sequences generated from the 190 
stools of a healthy Senegalese young man, and consisted of sequences best matching 191 
Marseillevirus among trashed metagenomic reads (Table 1) [20;55]. Subsequently, a close 192 
relative to Marseillevirus was isolated from this sample in Acanthamoeba and named 193 
Senegalvirus. Another metagenomic study identified reads matching the Marseillevirus 194 
genome in the blood of healthy blood donors [39]. This was confirmed by positive serology to 195 
Marseillevirus using immunofluorescence and Western blotting, and positive fluorescence in 196 
situ hybridization (FISH) and PCR on the blood and infected human lymphocytes. The 197 
presence of Marseillevirus was further detected by serology and PCR in other blood donors in 198 
France (IgG prevalence, 13-15%; DNA prevalence, 4-10%) [39;56], in Switzerland (IgG, 1.7-199 
2.5%) [57], and in polytransfused thalassemic patients in France (IgG, 23%; DNA, 9%) [56]. 200 
The detection of Marseillevirus DNA in blood donors and recipients has been a controversial 201 
issue, as it has not been observed in other studies [58-61]. However, the body of data 202 
supporting the presence of Marseillevirus in humans has continued to grow. In 2013, an 11-203 
month-old child was found to exhibit a very high level of IgG to Marseillevirus [62]. He 204 
presented an unexplained adenitis, and Marseillevirus DNA was detected in his blood, while 205 
the virus was visualized in the lymph node by immunohistochemistry and FISH.  206 
 Other giant viruses of amoebas 207 
 GVA other than mimiviruses and marseilleviruses, including pandoraviruses, 208 
faustoviruses and P. sibericum and M. sibericum, have been discovered during the past three 209 
years, which has prevented extensive investigation of their presence in humans until now 210 
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[13;17]. However, Pandoravirus inopinatum was isolated from the contact lens storage liquid 211 
of a keratitis patient [11] and sequences related to faustoviruses have been detected in 212 
metagenomes generated from human serum [13]. 213 
Metagenomic data 214 
 Metagenomics has emerged during the same period as GVA, representing a new 215 
technological approach and powerful tool, although it may lack sensitivity and may allow 216 
only detecting sequences best matching with GVA [20]. Nevertheless, causing diseases 217 
Detection in human metagenomes of sequences related to GVA tends to be correlated with the 218 
number of available genomes and time to their release. Mimivirus-like sequences have been 219 
detected in metagenomes generated from human coprolites, stools of diarrheal patients and 220 
healthy people, nasopharyngeal aspirates from patients with respiratory tract infections, 221 
buccal mucosa, saliva and retroauricular crease from healthy people, vagina from healthy 222 
women, and blood samples from healthy people or patients with liver diseases of various 223 
etiologies (Table 1) [20;21;63]. Notably, it has been recently reported that Mimiviridae 224 
representatives dominated, together with Poxviridae representatives, the human gut 225 
eukaryotic virome in metagenomic samples of the Human Microbiome Project [63]. 226 
Virophage-like sequences have also been found in the human gut [64]. In addition, 227 
Marseillevirus-like sequences have been detected in the buccal mucosa, retroauricular crease, 228 
vagina and stools from healthy people (Table 1) [20;63]. Recently, metagenome sequences 229 
best matching with pandoraviruses, Pithovirus sibericum, faustoviruses or virophages have 230 
also been detected in human plasma samples from patients with liver diseases [65]. 231 
 232 
Conclusion 233 
 The presence and impact of GVA and virophages in humans undoubtedly represent an 234 
important field that deserves further investigation in medicine. Such investigations are 235 
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difficult. However, it has been increasingly demonstrated that GVA can be present in humans. 236 
Evidence is particularly strong for mimiviruses and marseilleviruses, which were isolated 237 
from human feces, bronchoalveolar fluid and blood. Regarding the potential pathogenic role 238 
of these viruses in humans, the link between amoebal mimiviruses and pneumonia has been 239 
the most documented, whereas marseilleviruses have mostly been described in asymptomatic 240 
persons, and in an adenitis patient. Furthermore, for all these GVA, one must consider that 241 
their tremendous gene repertoires confer on them a strong potential for interaction with other 242 
organisms. It is also noteworthy that the closest relatives to faustoviruses are asfarviruses, 243 
which cause a common and severe disease in pigs [13]. Regarding other megaviruses, they 244 
include poxviruses, which are pathogenic in insects and mammals, including humans [66], 245 
and Acanthocystis turfacea chlorella virus, a phycodnavirus that was found in human 246 
pharyngeal samples and tentatively associated with cognitive disorders [67]. Until recently, 247 
the belief that all viruses are small entities probably limited the detection of GVA in humans. 248 
As this paradigm has been crumbling for a decade, future research should clarify the 249 
prevalence and consequence of their presence in humans. It appears particularly relevant to 250 
continue searching for mimiviruses in respiratory samples and stools, and for marseilleviruses 251 
in blood and in lymph nodes. Nevertheless, a broader panel of human samples from healthy 252 
and sick people should be tested; for instance, urine samples might be studied. In addition, 253 
investigations should involve a broad range of technological approaches, including serology, 254 
immunohistochemistry, immunofluorescence, FISH, targeted and random nucleic acid 255 
amplification, Sanger and next-generation sequencing, cytometry, microscopy, and high 256 
throughput culture isolation. Particularly, metagenomes currently extensively generated from 257 
human samples should be more exhaustively, thoroughly and recurrently screened for the 258 
presence of sequences best matching these GVA. Finally, experimental models on cells or 259 
animals would be helpful to gain a better understanding of the consequences of GVA 260 
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presence in humans. 261 
 262 
 263 
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FIGURE LEGENDS 478 
 479 
Figure 1. Schematic of the chronology of major findings that support the presence and 480 
possible pathogenic role in humans of giant viruses of amoebas 481 
 A majority of the findings are for mimiviruses and marseilleviruses, which were the 482 
oldest giant viruses described, in 2003 and 2009, respectively. Other giant viruses of amoebas 483 
have been described over the three last years. 484 
 485 
 Figure 2. Schematic of findings that support the presence and possible pathogenic role in 486 
humans of giant viruses of amoebas. 487 
 Supportive arguments involve a broad range of technological approaches including 488 
serology, immunohistochemistry, immunofluorescence, culture isolation, electron 489 
microscopy, fluorescence in situ hybridization (FISH), targeted and random nucleic acid 490 
amplification, qPCR, or Sanger and next-generation sequencing. Green and red circles 491 
indicate human body sites for which GVA evidence were obtained in healthy people and in 492 
diseased people, respectively. 493 
 494 
 495 
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TABLE 496 
Table 1. Summary of evidence of associations of mimiviruses or marseilleviruses with humans and of a possible pathogenic role  497 
 498 
Technical approaches Evidence for mimiviruses Evidence for marseilleviruses Elements to consider for causality 
Serology Presence of specific IgG and IgM antibodies to Mimivirus in 
pneumonia patients 
Greater seroprevalence in pneumonia patients than controls 
Mimivirus seroconversion in pneumonia patients, including one 
individual who manipulated the virus (reactivity to 23 
Mimivirus proteins) 
Serological reactivities to the Sputnik virophage in two patients 
(reactivity to 2 virophages proteins); seroconversion in one 
case 
IgG detection in blood donors, young health adults, 
multitransfused thalassemia patients, and a lymphadenitis 
patient 
 
Recurrent evidence of serological 
reactivities, including in association with 
Mimivirus isolation in one case; 
seroconversion to the Mimivirus and the 
Sputnik virophage in patients; association 
with Mimivirus handling in a patient with 
unexplained pneumonia, and with 
hospital-acquired pneumonia 
Detection of antibodies to Marseillevirus in 
association with Marseillevirus 
antigen/DNA detection in a single case-
patient  
Immunodetection  Detection of Marseillevirus antigens by immunofluorescence 
and immunochemistry in a lymph node adenitis 
Association of Marseillevirus with 
lymphadenitis 
Molecular detection Conventional PCR: Mimivirus DNA found in a 
broncholalveolar fluid and a serum sample from two 
pneumonia patients 
Conventional PCR: Marseillevirus DNA detection in the 
serum from blood donors, multitransfused thalassemia 
patients, and a lymphadenitis patient 
Association of Mimivirus with unexplained 
pneumonia and of Marseillevirus with 
lymphadenitis 
  Detection of Marseillevirus DNA by fluorescence in situ 
hybridization in a lymph node adenitis 
 
 Metagenomics: Detection in metagenomes generated from 
human coprolites, stools of diarrheal patients and healthy 
people, nasopharyngeal aspirates from patients with respiratory 
tract infections, buccal mucosa, saliva and retroauricular crease 
from healthy people, vagina from healthy women, and blood 
samples from healthy people or patients with liver diseases of 
various etiologies; detection of virophage-like sequences in the 
human gut 
Metagenomics: Marseillevirus-like sequences detection in the 
buccal mucosa, retroauricular crease, vagina and stools from 
healthy people 
 
Culture isolation Isolation from a broncholalveolar fluid and a faeces sample from 
two pneumonia patients 
 Association of Mimivirus with unexplained 
pneumonia 
Experimental models 
 
Cells: Entry in various human myeloid cells including circulating 
monocytes, monocyte-derived macrophages and 
myelomonocytic cells; entry in of mouse myeloid cells; 
productive infection of macrophage by Mimivirus post-
internalization; replication in total human peripheral blood 
mononuclear cells; interaction with type I IFN production in 
these cells 
Cells: Inoculation of immortalized human T lymphocyte cells 
with a serum sample positive for Giant blood Marseillevirus 
(GBM) DNA led to virus DNA detection in the culture 
supernatant, and viral DNA and virions detection within 
these cells 21 days post-infection by PCR, fluorescence in 
situ hybridization, or transmission electron microcopy 
 
 Animal: Pneumonia induction in mice inoculated 
intracardiacally 
 Mimivirus causes pneumonia in mice 
References for quoted studies are included in the text499 
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Box 1. Evolving criteria for proof of disease causation that can be applied to viruses 500 
 501 
Henle, Loeffler and Koch’s postulate (1884-1890) [29] 502 
1. The microorganism must be found in abundance in all organisms suffering from the 503 
disease, but should not be found in healthy animals. 504 
2. The microorganism must be isolated from a diseased organism and grown in pure culture. 505 
3. The cultured microorganism should cause disease when introduced into a healthy organism.  506 
4. The microorganism must be re-isolated from the inoculated, diseased experimental host and 507 
identified as being identical to the original specific causative agent. 508 
 509 
Rivers’ criteria for proof of viral disease causation (1937) [31] 510 
1. A specific virus must be found associated with a disease with a degree of regularity. 511 
2. The virus must be shown to occur in the sick individual not as an incidental or accidental 512 
finding but as the cause of the disease under investigation. 513 
3. Information concerning the presence of antibodies against the agent and the time of their 514 
appearance in the serum of patients is equally important as evidence of etiological 515 
significance of the virus. 516 
 517 
Huebner's prescription for the virologist's dilemma: conditions necessary for 518 
establishing a virus as cause of a specific human disease (1957) [32] 519 
1. Virus must be a "real" entity: A new virus must be well established by passage in the 520 
laboratory in animal or tissue cultures. 521 
2. Origin of virus: the virus must be repeatedly isolated from human specimens and shown not 522 
to be a viral contaminant of the experimental animals, cells, or media employed to grow it. 523 
3. Antibody response: An increase in neutralizing or other serologically demonstrable 524 
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antibodies should regularly result from active infection. 525 
4. Characterization and comparison with known agents: A new virus should be fully 526 
characterized and compared with other agents including host and host-cell ranges, pathologic 527 
lesions, types of cytopathogenic effects, size, susceptibility to physical agents, etc. 528 
5. Constant association with specific illness: The virus must be constantly associated with any 529 
well-defined clinical entity and isolated from diseased tissue, if available. 530 
6. Studies with human volunteers: Human beings inoculated with a newly recognized agent in 531 
"double blind" studies should reproduce the clinical syndrome. 532 
7. Epidemiologic studies: Both "cross-sectional" and "longitudinal" studies of community or 533 
institutional groups to identify patterns of infection and disease. 534 
8. Prevention by a specific vaccine: One of the best ways to establish an agent as the cause. 535 
9. Financial support: A consideration so absolutely necessary that it deserves to be called a 536 
postulate. 537 
 538 
Evans’s criteria for proof of disease causation: a unified concept appropriate for viruses 539 
as causative agents of disease based on the Henle–Koch postulates (1976) [33] 540 
1. Prevalence of the disease is significantly higher in subjects exposed to the putative virus 541 
than in those not so exposed. 542 
2. Incidence of the disease is significantly higher in subjects exposed to the putative virus than 543 
in those not so exposed (prospective studies). 544 
3. Evidence of exposure to the putative virus is present more commonly in subjects with the 545 
disease than in those without the disease.  546 
4. Temporally, the onset of disease follows exposure to the putative virus, always following 547 
an incubation period. 548 
5. A regular pattern of clinical signs follows exposure to the putative virus, presenting a 549 
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graded response, often from mild to severe. 550 
6. A measurable host immune response, such as an antibody response and/or a cell-mediated 551 
response, follows exposure to the putative virus. In those individuals lacking prior experience, 552 
the response appears regularly, and in those individuals with prior experience, the response is 553 
anamnestic.  554 
7. Experimental reproduction of the disease follows deliberate exposure of animals to the 555 
putative virus, but nonexposed control animals remain disease free. Deliberate exposure may 556 
be in the laboratory or in the field, as with sentinel animals. 557 
8. Elimination of the putative virus and/or its vector decreases the incidence of the disease. 558 
9. Prevention or modification of infection, via immunization or drugs, decreases the incidence 559 
of the disease. 560 
10. The whole thing should make biologic and epidemiologic sense. 561 
 562 
Fredricks and Relman’s molecular guidelines for establishing microbial disease 563 
causation (1996) [34] 564 
1. A nucleic acid sequence belonging to a putative pathogen should be present in most cases 565 
of an infectious disease. Microbial nucleic acids should be found preferentially in those 566 
organs or gross anatomic sites known to be diseased (i.e., with anatomic, histologic, chemical, 567 
or clinical evidence of pathology) and not in those organs that lack pathology. 568 
2. Fewer, or no, copy numbers of pathogen associated nucleic acid sequences should occur in 569 
hosts or tissues without disease. 570 
3. With resolution of disease (for example, with clinically effective treatment), the copy 571 
number of pathogen-associated nucleic acid sequences should decrease or become 572 
undetectable. With clinical relapse, the opposite should occur. 573 
4. When sequence detection predates disease, or sequence copy number correlates with 574 
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severity of disease or pathology, the sequence-disease association is more likely to be a causal 575 
relationship. 576 
5. The nature of the microorganism inferred from the available sequence should be consistent 577 
with the known biological characteristics of that group of organisms. When phenotypes (e.g., 578 
pathology, microbial morphology, and clinical features) are predicted by sequence-based 579 
phylogenetic relationships, the meaningfulness of the sequence is enhanced. 580 
6. Tissue-sequence correlates should be sought at the cellular level: efforts should be made to 581 
demonstrate specific in situ hybridization of microbial sequence to areas of tissue pathology 582 
and to visible microorganisms or to areas where microorganisms are presumed to be located. 583 
7. These sequence-based forms of evidence for microbial causation should be reproducible. 584 
 585 
Metagenomic Koch’s postulates (2012) [35]  586 
Comparison between a diseased and healthy control animal shows a significant difference 587 
between the metagenomic libraries (depicted by the histograms of relative abundance reads). 588 
In order to fulfill the metagenomic Koch’s postulates:  589 
1. The metagenomic traits in diseased subject must be significantly different from healthy 590 
subject. 591 
2. Inoculation of samples from the disease animal into the healthy control must lead to the 592 
induction of the disease state. Comparison of the metagenomes before and after inoculation 593 
should suggest the acquisition or increase of new metagenomic traits. New traits can be 594 
purified by methods such as serial dilution or time-point sampling of specimens from a 595 
disease animal. 596 
3. Inoculation of the suspected purified traits into a healthy animal will induce disease if the 597 
traits form the etiology of the disease. 598 
 599 
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